Neuropace Inc
NASDAQ:NPCE

Watchlist Manager
Neuropace Inc Logo
Neuropace Inc
NASDAQ:NPCE
Watchlist
Price: 10.2 USD -4.32% Market Closed
Market Cap: 297.8m USD
Have any thoughts about
Neuropace Inc?
Write Note

Intrinsic Value

NPCE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NPCE stock under the Base Case scenario is 9.6 USD. Compared to the current market price of 10.2 USD, Neuropace Inc is Overvalued by 6%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NPCE Intrinsic Value
9.6 USD
Overvaluation 6%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Neuropace Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NPCE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NPCE?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Neuropace Inc

Provide an overview of the primary business activities
of Neuropace Inc.

What unique competitive advantages
does Neuropace Inc hold over its rivals?

What risks and challenges
does Neuropace Inc face in the near future?

Has there been any significant insider trading activity
in Neuropace Inc recently?

Summarize the latest earnings call
of Neuropace Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neuropace Inc.

Provide P/S
for Neuropace Inc.

Provide P/E
for Neuropace Inc.

Provide P/OCF
for Neuropace Inc.

Provide P/FCFE
for Neuropace Inc.

Provide P/B
for Neuropace Inc.

Provide EV/S
for Neuropace Inc.

Provide EV/GP
for Neuropace Inc.

Provide EV/EBITDA
for Neuropace Inc.

Provide EV/EBIT
for Neuropace Inc.

Provide EV/OCF
for Neuropace Inc.

Provide EV/FCFF
for Neuropace Inc.

Provide EV/IC
for Neuropace Inc.

Show me price targets
for Neuropace Inc made by professional analysts.

What are the Revenue projections
for Neuropace Inc?

How accurate were the past Revenue estimates
for Neuropace Inc?

What are the Net Income projections
for Neuropace Inc?

How accurate were the past Net Income estimates
for Neuropace Inc?

What are the EPS projections
for Neuropace Inc?

How accurate were the past EPS estimates
for Neuropace Inc?

What are the EBIT projections
for Neuropace Inc?

How accurate were the past EBIT estimates
for Neuropace Inc?

Compare the revenue forecasts
for Neuropace Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neuropace Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neuropace Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neuropace Inc compared to its peers.

Compare the P/E ratios
of Neuropace Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Neuropace Inc with its peers.

Analyze the financial leverage
of Neuropace Inc compared to its main competitors.

Show all profitability ratios
for Neuropace Inc.

Provide ROE
for Neuropace Inc.

Provide ROA
for Neuropace Inc.

Provide ROIC
for Neuropace Inc.

Provide ROCE
for Neuropace Inc.

Provide Gross Margin
for Neuropace Inc.

Provide Operating Margin
for Neuropace Inc.

Provide Net Margin
for Neuropace Inc.

Provide FCF Margin
for Neuropace Inc.

Show all solvency ratios
for Neuropace Inc.

Provide D/E Ratio
for Neuropace Inc.

Provide D/A Ratio
for Neuropace Inc.

Provide Interest Coverage Ratio
for Neuropace Inc.

Provide Altman Z-Score Ratio
for Neuropace Inc.

Provide Quick Ratio
for Neuropace Inc.

Provide Current Ratio
for Neuropace Inc.

Provide Cash Ratio
for Neuropace Inc.

What is the historical Revenue growth
over the last 5 years for Neuropace Inc?

What is the historical Net Income growth
over the last 5 years for Neuropace Inc?

What is the current Free Cash Flow
of Neuropace Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neuropace Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neuropace Inc

Current Assets 82.6m
Cash & Short-Term Investments 56.8m
Receivables 11.6m
Other Current Assets 14.2m
Non-Current Assets 13.7m
PP&E 13.3m
Other Non-Current Assets 425k
Current Liabilities 14.8m
Accounts Payable 2.2m
Accrued Liabilities 11.9m
Other Current Liabilities 749k
Non-Current Liabilities 71.7m
Long-Term Debt 59.3m
Other Non-Current Liabilities 12.4m
Efficiency

Earnings Waterfall
Neuropace Inc

Revenue
76.5m USD
Cost of Revenue
-20m USD
Gross Profit
56.4m USD
Operating Expenses
-79.5m USD
Operating Income
-23.1m USD
Other Expenses
-5m USD
Net Income
-28.1m USD

Free Cash Flow Analysis
Neuropace Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NPCE Profitability Score
Profitability Due Diligence

Neuropace Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
28/100
Profitability
Score

Neuropace Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

NPCE Solvency Score
Solvency Due Diligence

Neuropace Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Positive Net Debt
Long-Term Solvency
High D/E
30/100
Solvency
Score

Neuropace Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NPCE Price Targets Summary
Neuropace Inc

Wall Street analysts forecast NPCE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NPCE is 15.47 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.

Lowest
Price Target
8.08 USD
21% Downside
Average
Price Target
15.47 USD
52% Upside
Highest
Price Target
21 USD
106% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NPCE?

Click here to dive deeper.

Dividends

Neuropace Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NPCE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NPCE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Neuropace Inc Logo
Neuropace Inc

Country

United States of America

Industry

Health Care

Market Cap

303.7m USD

Dividend Yield

0%

Description

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.

Contact

CALIFORNIA
Mountain View
455 N. Bernardo Avenue
+16502372700.0
www.neuropace.com

IPO

2021-04-22

Employees

152

Officers

CEO, President & Director
Mr. Joel D. Becker
CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary
Ms. Rebecca L. Kuhn
Chief Medical Officer
Dr. Martha J. Morrell
Chief of Operations & Development
Mr. Dylan St. John
Acting General Counsel
Ms. Leah Akin
Vice President of Sales
Ms. Kelley Nicholas
Show More
Vice President of Human Resources
Ms. Amy Treadwell
Show Less

See Also

Discover More
What is the Intrinsic Value of one NPCE stock?

The intrinsic value of one NPCE stock under the Base Case scenario is 9.6 USD.

Is NPCE stock undervalued or overvalued?

Compared to the current market price of 10.2 USD, Neuropace Inc is Overvalued by 6%.

Back to Top